Piramal Pharma Ltd Share Price Today - Piramal Pharma Ltd Stock Price Live NSE/BSE

Piramal Pharma Ltd

NSE: PPLPHARMA BSE: 543635

₹161.87

(1.07%)

Fri, 08 May 2026, 08:51 pm

MTF 5xInvest in Piramal Pharma Ltd with 5x Leverage Buy with MTF

Market Cap212.88B

PE Ratio0

Dividend0.09

Health Technology

Pharmaceuticals: Major

24.5K

Piramal Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
24438.23
Net Profit
91.13
P/B
3.66
Sector P/E
34.49
P/E
325.36
EV/EBITDA
20.63
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
1.14
ROCE
6.43
Debt/Equity
0.60
EPS (TTM)
0
Dividend Yield
0
Book Value
61.42
Interest Cover
1.98

Analysis

No Result Found

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	34.86	34.86	34.86	34.86	34.95
FII	30.18	29.66	30.27	30.86	31.49
DII	15.61	15.69	14.89	14.26	14.78
Public	19.35	19.80	19.98	20.02	18.78
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

70.72

MACD

6.92

50 DMA

151.67

200 DMA

177.21

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	227.37	191.98	176.93	156.59	141.54	121.20	85.81
Fibonacci	191.98	178.46	170.11	156.59	143.07	134.72	121.20
Camarilla	171.60	168.36	165.11	156.59	158.63	155.38	152.14

Pivots Level: Classic

+70.78

227.37

+35.39

191.98

+20.33

176.93

156.59

Pivot Point

LTP: 179.85

-15.06

141.54

-35.39

121.20

-70.78

85.81

Moving Average

SMAEMA

Period

Value

10-EMA
167.40
20-EMA
160.99
30-EMA
157.90
50-EMA
156.59
100-EMA
161.52
200-EMA
172.88

Announcement Date	Purpose	Action	Ex Date
28 Apr 2026	board-meetings	Accounts, Quarterly Results
28 Jan 2026	board-meetings	Quarterly Results
05 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
16 Jun 2025	dividend	Final Dividend - Rs. - 0.14	16 Jul 2025
13 Jun 2025	agm
14 May 2025	dividend	₹0.14 Dividend /Share	16 Jul 2025
12 Jun 2024	dividend	Final Dividend - Rs. - 0.11	12 Jul 2024
11 Jun 2024	agm
10 May 2024	dividend	₹0.11 Dividend /Share	12 Jul 2024
27 Jul 2023	rights	5:46 Rights Issue of Equity Shares	02 Aug 2023

Piramal Pharma Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd

Lupin Ltd

Cipla Ltd

Piramal Pharma Ltd About

Piramal Pharma is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. We operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (“CDMO”) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (“APIs”), Finished dosage forms (“FDFs”), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (“CHG“) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and Piramal Consumer Healthcare (“PCH“) business, selling well-known OTC brands.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2020

Headquarters

CEO

Nandini Piramal

Employees

Contact

Website

http://www.piramalpharma.com

corporate.secretarial@piramal.com

Phone

Location

Ananta Bldg Piramal Corporate, Park LBS Marg Kurla west, Mumbai, Maharashtra, 400070

Year	History
2020	The company was incorporated on March 4, 2020 at Mumbai as a public limited company. The company acquired the pharmaceutical business from PEL. The company received a 20% Strategic Growth Investment by Carlyle. The company increased its stake to 100% in CCPL. Piramal Pharma and Navin Fluorine mutually agreed on Piramal increasing its stake to 100% in Convergence Chemicals. Piramal Pharma Solutions collaborated with Epirium Bio on an exclusive integrated development and manufacturing program for orphan drugs. Piramal Pharma Solutions announced an integrated development program with Bolt Biotherapeutics for immune-stimulating antibody conjugates and sterile fill-finish. Piramal Critical Care announced a strategic partnership with US-based pharmaceutical outsourcing facility Medivant Healthcare.
2021	The company acquired HPPL. Piramal Pharma Solutions announced the winner of its Inaugural Award for Excellence in Patient Centricity. Piramal Pharma Solutions entered into a Master Services Agreement with Plus Therapeutics, Inc. Piramal Pharma Limited's Consumer Products Division launched 'i-feel'.
2022	The company acquired a minority stake in Yapan Bio Private Limited. The Composite Scheme of Arrangement was sanctioned by the NCLT on August 12, 2022. Piramal Pharma Solutions announced the winner of its September 2022 Award for Excellence in Patient Centricity. Piramal Pharma Solutions launched ADCelerate, a rapid, integrated approach to taking ADCs to IND. Piramal Pharma Solutions held the grand opening ceremony for its new API plant at Aurora, Canada manufacturing site. Piramal Pharma Solutions' new API plant in Canada went online and initial production runs were successfully completed.
2023	The company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

Client Name	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	Sell	6856958	219.88	20 Feb 2025
GRAVITON RESEARCH CAPITAL LLP	Buy	6856958	219.7	20 Feb 2025
EAST BRIDGE CAPITAL MASTER FUND LIMITED	Sell	33643099	102.8	31 Oct 2023
EAST BRIDGE CAPITAL MASTER FUND I LIMITED	Buy	33643099	102.8	31 Oct 2023
THE VANGUARD GROUP INC AC VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND	Buy	6202912	94.71	16 Jun 2023
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC	Sell	10570466	94.48	16 Jun 2023
BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L	Buy	310097	158.49	01 Nov 2022
BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L	Sell	14066087	158.88	01 Nov 2022

Piramal Pharma Ltd News

Piramal Pharma to Attend Investor Conference on May 27

Piramal Pharma will participate in the 360 ONE Capital 16th Annual Investor Conference - Trinity India 2026 in Mumbai on May 27, 2026.

04 May 2026

companies

Piramal Pharma posts Q4FY26 conference call transcript

Piramal Pharma Limited has made the transcript of its Q4FY26 financial results conference call available on its website, complying with SEBI Regulation 30(6) requirements.

30 Apr 2026

companies

Jefferies Maintains Buy Rating on Piramal Pharma at ₹190

Jefferies maintains Buy rating with ₹190 target despite EBITDA estimate cuts of 8-21% for FY27-28, citing strong CDMO momentum and early-to-mid teens FY27 revenue growth guidance.

30 Apr 2026

companies

Piramal Pharma Eyes ADCs as Key Growth Driver for FY27+

Management highlights ADCs as meaningful growth driver for FY27-28 and beyond, with new customer additions and Phase 3 products strengthening pipeline amid strong medium-term outlook.

30 Apr 2026

companies

Piramal Pharma Makes Q4FY26 Conference Call Recording Available

Piramal Pharma Limited has made the audio recording of its Q4FY26 financial results conference call available on the company website following regulatory compliance requirements.

30 Apr 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800